Heidi Fettke1, Edmond M Kwan2,3, Arun A Azad2,3. 1. Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia. Heidi.Fettke@monash.edu. 2. Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia. 3. Department of Medical Oncology, Monash Health, Melbourne, Australia.
Abstract
BACKGROUND: The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clinical and radiographic tumour monitoring methods, the analysis of ctDNA provides a minimally-invasive and technically feasible approach to assess temporal and spatial molecular evolutions of the tumour landscape. The constantly advancing technological platforms available for ctDNA extraction and analysis allow greater analytical sensitivities than ever before. The potential translational impact of ctDNA as a blood-based biomarker for the identification, characterization and monitoring of cancer has been demonstrated in numerous proof-of-concept studies, with ctDNA analysis beginning to be applied clinically across multiple facets of oncology. CONCLUSIONS: In this review we discuss the biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer, and highlight important challenges and future directions for the integration of ctDNA into standardised patient care.
BACKGROUND: The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clinical and radiographic tumour monitoring methods, the analysis of ctDNA provides a minimally-invasive and technically feasible approach to assess temporal and spatial molecular evolutions of the tumour landscape. The constantly advancing technological platforms available for ctDNA extraction and analysis allow greater analytical sensitivities than ever before. The potential translational impact of ctDNA as a blood-based biomarker for the identification, characterization and monitoring of cancer has been demonstrated in numerous proof-of-concept studies, with ctDNA analysis beginning to be applied clinically across multiple facets of oncology. CONCLUSIONS: In this review we discuss the biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer, and highlight important challenges and future directions for the integration of ctDNA into standardised patient care.
Authors: Raquel Catarino; Maria M Ferreira; Helena Rodrigues; Ana Coelho; Ana Nogal; Abreu Sousa; Rui Medeiros Journal: DNA Cell Biol Date: 2008-08 Impact factor: 3.311
Authors: Paul A Vanderlaan; Norihiro Yamaguchi; Erik Folch; David H Boucher; Michael S Kent; Sidharta P Gangadharan; Adnan Majid; Michael A Goldstein; Mark S Huberman; Olivier N Kocher; Daniel B Costa Journal: Lung Cancer Date: 2014-01-28 Impact factor: 5.705
Authors: Michael J Overman; Janhavi Modak; Scott Kopetz; Ravi Murthy; James C Yao; Marshall E Hicks; James L Abbruzzese; Alda L Tam Journal: J Clin Oncol Date: 2012-11-05 Impact factor: 44.544
Authors: M Jamal-Hanjani; G A Wilson; S Horswell; R Mitter; O Sakarya; T Constantin; R Salari; E Kirkizlar; S Sigurjonsson; R Pelham; S Kareht; B Zimmermann; C Swanton Journal: Ann Oncol Date: 2016-01-28 Impact factor: 32.976
Authors: Muhammed Murtaza; Sarah-Jane Dawson; Katherine Pogrebniak; Oscar M Rueda; Elena Provenzano; John Grant; Suet-Feung Chin; Dana W Y Tsui; Francesco Marass; Davina Gale; H Raza Ali; Pankti Shah; Tania Contente-Cuomo; Hossein Farahani; Karey Shumansky; Zoya Kingsbury; Sean Humphray; David Bentley; Sohrab P Shah; Matthew Wallis; Nitzan Rosenfeld; Carlos Caldas Journal: Nat Commun Date: 2015-11-04 Impact factor: 14.919